Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0

作者：

Prezotti, A. ^{[1
,2
]}

Montalvao, S. ^{[1
]}

Marques, A. ^{[3
]}

Ferreira, C. ^{[4
]}

Oliveira, L. ^{[5
]}

Villaca, P. ^{[6
]}

Ferreira Filho, L. ^{[7
]}

Lorenzato, C. ^{[8
]}

Medina, S. ^{[1
]}

Araujo, F. ^{[9
]}

Ozelo, M. ^{[1
]}

机构：

[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil

[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil

[3] HEMORIO, Hematol, Rio De Janeiro, Brazil

[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil

[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil

[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil

[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil

[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil

[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO286-MON

引用

页码：366 / 366

页数：1

共 50 条

[31] Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII
Betts, JP
BRITISH MEDICAL JOURNAL, 1998, 316 (7141): : 1385 - 1385
[32] Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy
Peerlinck, K.
Hermans, C.
HAEMOPHILIA, 2006, 12 (06) : 579 - 590
[33] Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA
Miranda, G. G.
Rodgers, G. M.
HAEMOPHILIA, 2009, 15 (01) : 383 - 385
[34] B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study
Kessler, CM
Gill, JC
White, GC
Shapiro, A
Arkin, S
Roth, DA
Meng, X
Lusher, JM
HAEMOPHILIA, 2005, 11 (02) : 84 - 91
[35] Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A
Steele, M. R.
Nagel, K.
Chan, A. K. C.
HAEMOPHILIA, 2014, 20 (01) : E100 - E101
[36] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIII ARE IMMUNOLOGICALLY DISTINCT IN IN-VITRO ASSAYS
GILLES, JGG
SAINTREMY, JMR
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1213 - 1213
[37] Accumulation of factor VIII and von Willebrand factor during prophylaxis with a plasma-derived von Willebrand FACTOR/FACTOR VIII concentrate during the WIL-31 study
Kateryna, V. V.
Vdovin, V.
Timofeeva, M. A.
Khayat, C. D.
Inati, A.
Sidonio, R. F., Jr.
HAEMOPHILIA, 2024, 30 : 139 - 140
[38] Italian consumption of plasma-derived factor VIII after the SIPPET study
Traversa, Giuseppe
Trotta, Francesco
BLOOD TRANSFUSION, 2017, 15 (03) : 283 - 284
[39] STATUS OF CLINICAL INVESTIGATION OF HUMAN FACTOR-VIII DERIVED FROM RECOMBINANT DNA (RFVIII)
SCHWARTZ, RS
ABILDGAARD, C
ALEDORT, L
ARKIN, S
BLOOM, A
BRACKMANN, H
BRETTLER, D
DIETRICH, S
EGLI, J
FUJIMAKI, M
FUKUI, H
HILGARTNER, M
INWOOD, M
KASPER, C
KERNOFF, P
LEVINE, P
LUSHER, J
MANNUCCI, P
ROSE, E
SCHARRER, I
TRANSFUSION, 1990, 30 (03) : 277 - 277
[40] Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient
Rosenfeld, SB
Watkinson, KK
Thompson, BH
Macfarlane, DE
Lentz, SR
THROMBOSIS AND HAEMOSTASIS, 2002, 87 (05) : 925 - 926

← 1 2 3 4 5 →